Prognostic Significance of Venous Thromboembolic Events in Disseminated Germ Cell Cancer Patients

被引:10
作者
Gonzalez-Billalabeitia, Enrique [1 ,2 ]
Castellano, Daniel [3 ]
Sobrevilla, Nora [4 ]
Guma, Josep [5 ]
Hervas, David [6 ]
Luengo, Maria I. [1 ]
Aparicio, Jorge [7 ]
Sanchez-Munoz, Alfonso [8 ]
Mellado, Begona [9 ]
Saenz, Alberto [10 ]
Valverde, Claudia [11 ]
Fernandez, Antonio [12 ]
Margeli, Mireia [13 ]
Duran, Ignacio [14 ]
Fernandez, Sara [15 ]
Sastre, Javier [16 ]
Ros, Silverio [17 ]
Maroto, Pablo [18 ]
Manneh, Ray [3 ]
Cerezuela, Pablo [19 ]
Carmona-Bayonas, Alberto
机构
[1] Hosp Univ Morales Meseguer IMIB, Murcia, Spain
[2] Univ Catolica San Antonio Murcia UCAM, Murcia, Spain
[3] Hosp Univ 12 Octubre, Madrid, Spain
[4] Inst Nacl Cancerol, Mexico City, DF, Mexico
[5] URV, Hosp San Joan de Reus, IISSPV, Tarragona, Spain
[6] Inst Invest Sanitaria La Fe, Valencia, Spain
[7] Hosp Univ La Fe, Valencia, Spain
[8] Hos Univ Reg & Virgen de la Victoria Malaga, Invest Clin & Traslac Canc, Inst Invest Biomed Malaga IBIMA, Malaga, Spain
[9] Hosp Clin Barcelona, IDIBAPS, Serv Oncol Med, Barcelona, Spain
[10] Hosp Clin Lozano Blesa, Zaragoza, Spain
[11] Hosp Univ Vall dHebron, Barcelona, Spain
[12] Complejo Hosp Univ Albacete, Albacete, Spain
[13] Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol, Badalona, Spain
[14] Hosp Univ Virgen del Rocio, Seville, Spain
[15] Hosp Cent Asturias, Oviedo, Spain
[16] Hosp Clin San Carlos, Madrid, Spain
[17] Hosp Virgen Arrixaca, Murcia, Spain
[18] Hosp Santa Creu & Sant Pau, Barcelona, Spain
[19] Hosp Santa Lucia, Cartagena, Spain
来源
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2017年 / 109卷 / 04期
关键词
CISPLATIN-BASED CHEMOTHERAPY; RISK; SURVIVAL; TUMORS;
D O I
10.1093/jnci/djw265
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Disseminated germ cell cancers are at high risk of developing thromboembolic complications. We evaluated the prognostic value of venous thromboembolic events (VTE) in disseminated germ cell cancer. Methods: Patients with germ cell cancer receiving upfront platinum-containing chemotherapy between 2004 and 2014 were pooled from the Spanish Germ Cell Cancer Group (SGCCG) registry and reviewed for the presence of VTE. Results were validated in an independent international group of patients. We used a penalized Cox proportional hazards model including VTE as a time-varying covariate to identify and validate prognostic factors. All statistical tests were two-sided. Results: The SGCCG registry identified 416 patients from 14 referral institutions. With a median follow-up of 49 months, VTEs were observed in 9% of patients (n = 38). Events occurred at diagnosis, during chemotherapy, and after chemotherapy in 2.6%, 5.0%, and 1.4% of patients, respectively. VTE was associated with shorter progression-free survival (PFS; hazard ratio [HR] = 2.29, 95% confidence interval [CI] = 1.18 to 4.47, P = .02) and overall survival (OS; HR = 5.14, 95% CI = 2.22 to 11.88, P < .001). In multivariable analysis, the effect was consistent in the intermediate-risk group, both for PFS (HR = 9.52 95% CI = 2.48 to 36.58, P < .001) and OS (HR = 12.84, 95% CI = 2.01 to 82.02, P = .007). VTE at diagnosis is also an adverse prognostic variable for progression-free survival (HR = 4.64, 95% CI = 2.04 to 10.54, P < .001) and for overall survival (HR = 6.28, 95% CI = 1.68 to 17.10, P = .01). These results were validated in an independent international cohort that included 241 patients from four hospitals. Conclusions: VTE is an independent adverse prognostic factor in disseminated germ cell cancers, in particular for the intermediate prognostic group of the International Germ Cell Cancer Collaborative Group classification. The presence of VTE at diagnosis has also prognostic significance and should be further explored in future prognostic classifications.
引用
收藏
页数:6
相关论文
共 23 条
[1]   Venous thromboembolism in patients with colorectal cancer: Incidence and effect on survival [J].
Alcalay, A ;
Wun, T ;
Khatri, V ;
Chew, HK ;
Harvey, D ;
Zhou, H ;
White, RH .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (07) :1112-1118
[2]  
[Anonymous], 1997, J Clin Oncol, V15, P594
[3]   Secondary Raynaud's phenomenon and other late vascular complications following chemotherapy for testicular cancer [J].
Berger, CC ;
Bokemeyer, C ;
Schneider, M ;
Kuczyk, MA ;
Schmoll, HJ .
EUROPEAN JOURNAL OF CANCER, 1995, 31A (13-14) :2229-2238
[4]   Incidence of venous thromboembolism and the impact on survival in breast cancer patients [J].
Chew, Helen K. ;
Wun, Theodore ;
Harvey, Danielle J. ;
Zhou, Hong ;
White, Richard H. .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (01) :70-76
[5]  
Chew HK, 2006, ARCH INTERN MED, V166, P458
[6]  
Dieckmann KP, 2011, ANTICANCER RES, V31, P4501
[7]   2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer [J].
Farge, Dominique ;
Frere, Corinne ;
Connors, Jean M. ;
Ay, Cihan ;
Khorana, Alok A. ;
Muno, Andres Z. ;
Brenner, Benjamin ;
Kakkar, Ajay ;
Rafii, Hanadi ;
Solymoss, Susan ;
Brilhante, Dialina ;
Monreal, Manuel ;
Bounameaux, Henri ;
Pabinger, Ingrid ;
Douketis, James .
LANCET ONCOLOGY, 2019, 20 (10) :E566-E581
[8]   BIAS REDUCTION OF MAXIMUM-LIKELIHOOD-ESTIMATES [J].
FIRTH, D .
BIOMETRIKA, 1993, 80 (01) :27-38
[9]  
HALL MR, 1988, LANCET, V2, P1259
[10]   Testicular Cancer: A Reflection on 50 Years of Discovery [J].
Hanna, Nasser ;
Einhorn, Lawrence H. .
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (28) :3085-+